Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/22307
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKakafika, A. I.en
dc.contributor.authorLiberopoulos, E. N.en
dc.contributor.authorKaragiannis, A.en
dc.contributor.authorAthyros, V. G.en
dc.contributor.authorMikhailidis, D. P.en
dc.date.accessioned2015-11-24T19:23:26Z-
dc.date.available2015-11-24T19:23:26Z-
dc.identifier.issn1570-1611-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/22307-
dc.rightsDefault Licence-
dc.subjectAdipose Tissue/metabolismen
dc.subjectAdiposityen
dc.subjectAnimalsen
dc.subjectAspirin/therapeutic useen
dc.subjectCardiovascular Diseases/blood/drug therapy/*etiology/metabolismen
dc.subjectCholesterol, HDL/blooden
dc.subjectClofibric Acid/therapeutic useen
dc.subjectDyslipidemias/blood/*complications/drug therapy/metabolismen
dc.subjectFactor VII/metabolismen
dc.subjectFibrinolytic Agents/therapeutic useen
dc.subjectHumansen
dc.subjectHydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic useen
dc.subjectHypolipidemic Agents/therapeutic useen
dc.subjectInflammation Mediators/metabolismen
dc.subjectInsulin Resistanceen
dc.subjectLife Styleen
dc.subjectLipoproteins, LDL/blooden
dc.subjectMetabolic Syndrome X/blood/*complications/drug therapy/metabolismen
dc.subjectObesity/blood/complications/drug therapy/metabolismen
dc.subjectPlasminogen Activator Inhibitor 1/blood/metabolismen
dc.subjectThrombophilia/blood/*complications/drug therapy/metabolismen
dc.subjectTriglycerides/blooden
dc.subjectvon Willebrand Factor/metabolismen
dc.titleDyslipidaemia, hypercoagulability and the metabolic syndromeen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/16842135-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2006-
heal.abstractThe metabolic syndrome is a clustering of risk factors including central obesity, insulin resistance, dyslipidaemia and hypertension. This syndrome is associated with increased risk of cardiovascular disease and is a common early abnormality in the development of type 2 diabetes. The pathogenesis of the syndrome has multiple origins. Obesity and sedentary lifestyle coupled with genetic factors interact to produce the syndrome. Here, we consider two components of the metabolic syndrome, dyslipidaemia and hypercoagulability.en
heal.journalNameCurr Vasc Pharmacolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
There are no files associated with this item.


This item is licensed under a Creative Commons License Creative Commons